The evidence is strong that two modifiable factors predict how long people live. In a cohort of more than 120,000 adults who underwent treadmill testing, cardiorespiratory fitness was inversely associated with long-term mortality with no observed upper limit of benefit (Mandsager et al., JAMA Network Open, 2018). In the PREDIMED randomized trial of about 7,400 people at high cardiovascular risk, a Mediterranean diet supplemented with extra-virgin olive oil or nuts reduced major cardiovascular events compared with a reduced-fat diet (Estruch et al., New England Journal of Medicine, 2018). This is why exercise and diet are in every plan.
The evidence for NAD+ precursors is emerging. In a placebo-controlled trial of 25 postmenopausal women with prediabetes, ten weeks of oral NMN increased skeletal-muscle insulin sensitivity and insulin signaling (Yoshino et al., Science, 2021). It did not measure aging outcomes, and intravenous NAD+ has not been tested in a comparable trial.
The evidence for senolytics is emerging. In an open-label pilot of nine patients with diabetic kidney disease, three days of oral dasatinib plus quercetin reduced senescent-cell markers in adipose tissue and skin within eleven days (Hickson et al., EBioMedicine, 2019). Nine patients and no control group is a signal, not a result.
What the evidence does not show: no intervention on this page has been shown in a randomized trial to extend human lifespan or to lower biological age as measured by an epigenetic clock. What the trials measure are markers and function, and that is what we measure too.